CD8+ and CD4+ donor memory T cells-expressing HA1-specific TCR

{
  "id": "MLC-T-ONC-012419",
  "term": "CD8+ and CD4+ donor memory T cells-expressing HA1-specific TCR",
  "field": "Oncology and biomedicine",
  "definition": "A preparation of CD4+ and CD8+ central memory (CM) T lymphocytes isolated from the peripheral blood of a transplant donor and transduced with a lentiviral vector (LV) (pRRLSIN) expressing a minor H antigen (HA-1(H); HA1(H)) T-cell receptor (TCR) containing the suicide gene inducible caspase 9 (iCasp9 or iC9)-HA1 TCR2-RQR-CD8 transgene (pRRLSIN iC9-HA1 TCR2-RQR-CD8; HA-1 TCR LV), with potential immunostimulating and antineoplastic activities. Upon intravenous administration and after allogeneic hematopoietic stem cell transplantation (HSCT), the CD8+ and CD4+ donor memory T cells-expressing HA1-specific TCR are directed to and induce selective toxicity in HA1-expressing tumor cells. iCasp9 consists of a human FK506 drug-binding domain with an F36V mutation (FKBP12-F36V) linked to human caspase 9. If administration of the T cells lead to unacceptable side effects, a dimerizing agent rimiducid (AP1903), which binds to the FKBP12-F36V drug-binding domain and activates caspase 9, can be administered; caspase-9 activation results in the apoptosis of the administered TCR-modified T cells. HA1(H) is a tumor-associated antigen (TAA) that is selectively and highly expressed on leukemic stem cells and blasts, but not in normal non-hematopoietic cells. RQR includes a CD20 epitope, and a CD34 epitope that facilitates both purification and cell tracking of the transduced T cells with an anti-CD34 monoclonal antibody.",
  "synonyms": [
    "HA-1 TCR T cells",
    "HA-1 TCR CD8+ and CD4+ Tm cells",
    "CD8+ and CD4+ donor memory T cells-expressing pRRLSIN iC9-HA1 TCR2-RQR-CD8"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/cd8-plus-and-cd4-plus-donor-memory-t-cells-expressing-ha1-specific-tcr/"
}